MicroRNA 21 and microRNA 10b: early diagnostic biomarkers of breast cancer in Egyptian females

Ali, M. Idul; Gayar, Dina El; Hany, Normeen; Ezzat, Abdel Hamid Hussein; Zeyada, Reham

doi:10.1186/s43046-022-00115-6

Cited by 7 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results were The miR-21 diagnostic performance was constructed utilizing ROC curve analysis, which had good sensitivity and specificity performance in discrimination of patients with breast cancer from study participants. In concordance with our results, Han et al, 24 Papadaki et al, 32 and Ali et al, 33 have identified miR-21 expression as a discriminator biomarker between breast cancer and healthy controls, providing a potential diagnostic candidate. As far as we know, this is the first investigation pointed to the correlation of TGF-β with the miR-21/MEG-2 expression.…”

Section: Discussionsupporting

confidence: 93%

Signature of miR-21 and MEG-2 and their correlation with TGF-β signaling in breast cancer

et al. 2023

View full text Add to dashboard Cite

Breast cancer is highly prevalent and considered the main challenge to public health among females in Egypt as in other countries. MicroRNA-21 (miR-21) and MEG-2 are noncoding RNA attributed to their aberrant expression in several diseases, including breast cancer. This study aimed to assess the reliability of serum expression levels of miR-21 and MEG-2 in discriminating stages of breast cancer and scrutinize their correlations with the targeted transforming growth factor-beta (TGF-β) expression. One hundred and 30 participants whose ages ranged from 28 to 62 years were included in this study, divided into one hundred breast cancer patients and 30 healthy participants. miR-21 and TGF-β expression levels showed upregulation in patients with BC and elevated miR-21/TGF-β levels consistent with the BC stage. In addition, LncRNA (MEG-2) showed down-regulation in patients with BC. MEG-2 expression levels revealed a gradual decrease consistent with the BC stage. In addition, a negative relationship between the MEG-2 and the miR-21 and TGF-β differential expression was also noticed. This study suggested that miR-21 and MEG-2 can be used as prospective diagnostic biomarkers and emphasized the crucible role of TGF-β as therapeutic targets for BC.

show abstract

Section: Discussionsupporting

confidence: 93%

Signature of miR-21 and MEG-2 and their correlation with TGF-β signaling in breast cancer

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Ibrahim et al [ 22 ] also reported the upregulation of miR-10b in a cohort of BC patients, a result consistent with the findings from the recent study conducted by Ali et al in 2022 [ 23 ]. Aligning with these observations, Ali et al found that serum miR-10b levels were upregulated in BC patients compared to healthy controls.…”

Section: Resultssupporting

confidence: 84%

Assessment of miRNA-10b Expression Levels as a Potential Precursor to Metastasis in Localized and Locally Advanced/Metastatic Breast Cancer among Iraqi Patients

Abdallah,

Aziz,

Alsammarraie

2024

International Journal of Breast Cancer

View full text Add to dashboard Cite

Breast cancer (BC) stands as the most prevalent form of carcinoma among women, ranking as the second leading cause of cancer-related mortality in the female population. The objective of this study is to assess the expression of miR-10b and determine its diagnostic and prognostic significance in breast cancer patients across various disease stages. The investigation was carried out in Baghdad at the Oncology Teaching Hospital within Baghdad Medical City and the Oncology Unit at Al-Yarmouk Teaching Hospital. A total of 150 samples were included and divided into two groups: the blood group consisting of 90 samples (including control subjects, localized BC patients, and those with metastatic and locally advanced BC) and the tissue group comprising 60 samples (representing both benign and malignant BC cases). The study spanned from March 2022 to January 2023, with patients’ ages ranging from 24 to 75 years. The primary focus of this investigation was to identify the gene expression of miRNA-10b in all sample types. This was achieved by measuring gene expression levels and normalizing them to the level of a housekeeping gene (U6), and quantification was carried out considering the ΔCt value and the fold change method (2−ΔΔCt). The results revealed an upregulated fold expression of miRNA-10b, particularly in locally advanced and metastatic BC, where the expression was significantly higher compared to the other groups, with a fold expression of 1.770±0.1070. In localized breast cancer, the fold expression was 1.624±0.064, and in malignant tissue, it measured 1.546±0.06754, all relative to apparently healthy control subjects. In summary, our research provides compelling evidence supporting the classification of miRNA-10b as an oncogenic factor in BC. The central involvement of miRNA-10b in the tumorigenic processes of BC highlights its reference for developing novel targeted therapeutic interventions and detection biomarkers for BC treatment. Notably, elevated expression of miRNA-10b was observed in BC tissues, correlating with an unfavorable distant metastasis-free survival outcome.

show abstract

“…In total, 16 142 articles were identified in the aforementioned databases (Table 1). However, 234 articles were retained for full reading, following the elimination of duplicates and articles whose title and abstract did not meet the eligibility criteria; of these, only 136 12…”

Section: Resultsmentioning

confidence: 99%

“…As shown in Table 6, highlighted in gray, 28 biomarkers presenting a Sensitivity greater than 90% were identified: miR-17-5p, miR-155, miR-222, 89 miR-202, 60 PTEN, SMAD4, 24 APC, RARB2, 115 miRNA-222, miRNA-373, 92 miR-27a, 85 cfDNA methylation score, 25 HER2 mRNA, 95 miR-21, 28 polymorphism -31G/C in survivin promoter gene, 79 hsa-miR25-3p, hsa-miR-548ar-5p, 80 miR-598-3p, miR-1246, 105 miR-495, 117 telomeric sequences in cfDNA, 121 miR-30c, miR-148a, 39 miR-185-3p, 49 miR-34a, 17 miR10b, miR21, 12 and miRNA-373. 34…”

Section: Resultsmentioning

confidence: 99%

“…Abbreviations: BC, breast cancer; HER2, human epidermal growth factor 2; LB, liquid biopsy. As shown in Table 6, highlighted in gray, 28 biomarkers presenting a Sensitivity greater than 90% were identified: miR-17-5p, miR-155, miR-222, 89 miR-202, 60 PTEN, SMAD4, 24 APC, RARB2, 115 miRNA-222, miRNA-373, 92 miR-27a, 85 cfDNA methylation score, 25 HER2 mRNA, 95 miR-21, 28 polymorphism -31G/C in survivin promoter gene, 79 hsa-miR25-3p, hsa-miR-548ar-5p, 80 miR-598-3p, miR-1246, 105 miR-495, 117 telomeric sequences in cfDNA, 121 miR-30c, miR-148a, 39 miR-185-3p, 49 miR-34a, 17 miR10b, miR21, 12 and miRNA-373. 34 As shown in Table 7, highlighted in gray, 16 biomarker panels in peripheral blood can be observed 19,22,27,29,30,42,44,54,61,81,93,98,106,111,112,123 and 2 biomarker panels in saliva 74,86 with a sensitivity greater than 90%.…”

Section: Diagnostic Role Of Lb In Bcmentioning

confidence: 99%

See 1 more Smart Citation

Cancer Biomarkers in Liquid Biopsy for Early Detection of Breast Cancer: A Systematic Review

Duque

Manterola

Otzen

et al. 2022

Clin Med Insights Oncol

View full text Add to dashboard Cite

Background: Breast cancer (BC) is the most common neoplasm in women worldwide. Liquid biopsy (LB) is a non-invasive diagnostic technique that allows the analysis of biomarkers in different body fluids, particularly in peripheral blood and also in urine, saliva, nipple discharge, volatile respiratory fluids, nasal secretions, breast milk, and tears. The objective was to analyze the available evidence related to the use of biomarkers obtained by LB for the early diagnosis of BC. Methods: Articles related to the use of biomarkers for the early diagnosis of BC due to LB, published between 2010 and 2022, from the databases (WoS, EMBASE, PubMed, and SCOPUS) were included. The MInCir diagnostic scale was applied in the articles to determine their methodological quality (MQ). Descriptive statistics were used, as well as determination of weighted averages of each variable, to analyze the extracted data. Sensitivity, specificity, and area under the curve values for specific biomarkers (individual or in panels) are described. Results: In this systematic review (SR), 136 articles met the selection criteria, representing 17 709 patients with BC. However, 95.6% were case-control studies. In 96.3% of cases, LB was performed in peripheral blood samples. Most of the articles were based on microRNA (miRNA) analysis. The mean MQ score was 25/45 points. Sensitivity, specificity, and area under the curve values for specific biomarkers (individual or in panels) have been found. Conclusions: The determination of biomarkers through LB is a useful mechanism for the diagnosis of BC. The analysis of miRNA in peripheral blood is the most studied methodology. Our results indicate that LB has a high sensitivity and specificity for the diagnosis of BC, especially in early stages.

show abstract

MicroRNA 21 and microRNA 10b: early diagnostic biomarkers of breast cancer in Egyptian females

Cited by 7 publications

References 23 publications

Signature of miR-21 and MEG-2 and their correlation with TGF-β signaling in breast cancer

Signature of miR-21 and MEG-2 and their correlation with TGF-β signaling in breast cancer

Assessment of miRNA-10b Expression Levels as a Potential Precursor to Metastasis in Localized and Locally Advanced/Metastatic Breast Cancer among Iraqi Patients

Cancer Biomarkers in Liquid Biopsy for Early Detection of Breast Cancer: A Systematic Review

Contact Info

Product

Resources

About